Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fyhrquist

Showing results (271-280 of 279) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 279 results.
Rheumatology International|January 1, 1997
Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritisD Nordström, Y Lindroth, L Marsal, et al.
Life Sciences|January 1, 1989
Experimental ductus arteriosus: the relationships of atrial pressure, dilatation and flow with ANF secretionE Pesonen, F Sherman, J Breuer, et al.
The European Respiratory Journal|November 1, 1990
Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosisC Prior, R A Barbee, P M Evans, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Journal of Human Hypertension|April 23, 2004
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE studyH M Reims, S E Kjeldsen, W E Brady, et al.
Pageof 28

Showing results (271-280 of 279) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
Rheumatology International|January 1, 1997
Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritisD Nordström, Y Lindroth, L Marsal, et al.
Life Sciences|January 1, 1989
Experimental ductus arteriosus: the relationships of atrial pressure, dilatation and flow with ANF secretionE Pesonen, F Sherman, J Breuer, et al.
The European Respiratory Journal|November 1, 1990
Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosisC Prior, R A Barbee, P M Evans, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Journal of Human Hypertension|April 23, 2004
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE studyH M Reims, S E Kjeldsen, W E Brady, et al.
Pageof 28